Showing results (101-110 of 189) with videos related to
Sort By:
Pageof 19
Gynecologic Oncology|August 9, 2011
Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancerSeiji Mabuchi, Mika Okazawa, Fumiaki Isohashi, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 28, 2012
The prognostic significance of multiple pelvic node metastases in cervical cancer patients treated with radical hysterectomy plus adjuvant chemoradiotherapyMika Okazawa, Seiji Mabuchi, Fumiaki Isohashi, et al.International Journal of Radiation Oncology, Biology, Physics|June 26, 2012
Dose-volume histogram predictors of chronic gastrointestinal complications after radical hysterectomy and postoperative concurrent nedaplatin-based chemoradiation therapy for early-stage cervical cancerFumiaki Isohashi, Yasuo Yoshioka, Seiji Mabuchi, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 10, 2013
A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodesSeiji Mabuchi, Ryoko Takahashi, Fumiaki Isohashi, et al.Gynecologic Oncology|February 18, 2016
A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodesSeiji Mabuchi, Fumiaki Isohashi, Takeshi Yokoi, et al.Journal of Radiation Research|November 28, 2014
Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factorsMasateru Fujiwara, Fumiaki Isohashi, Seiji Mabuchi, et al.International Journal of Women'S Health|November 29, 2017
Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifeneAska Toda, Kenjiro Sawada, Akihiko Yoshimura, et al.The Journal of Obstetrics and Gynaecology Research|October 29, 2025
Rare Intronic Variants Altering Splicing Cause Lynch Syndrome: Two Case ReportsYumi Takimoto, Hiroshi Tsubamoto, Tomokazu Wakatsuki, et al.Endocrinology|December 3, 2003
Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatinSeiji Mabuchi, Masahide Ohmichi, Akiko Kimura, et al.Gynecologic Oncology|April 26, 2011
Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancerSeiji Mabuchi, Yuri Matsumoto, Fumiaki Isohashi, et al.Pageof 19